L-arginine reverses alterations in drug disposition induced by spinal cord injury by increasing hepatic blood flow.
High hepatic extraction drugs--such as phenacetin, methylprednisolone, and cyclosporine--exhibit an increased bioavailability after acute spinal cord injury (SCI) due to an impaired clearance. For these drugs, metabolic clearance depends on hepatic blood flow. Thus, it is possible that pharmacokinetic alterations can be reversed by increasing liver perfusion. Therefore, we evaluated the effect of L-arginine, a nitric oxide precursor, on the pharmacokinetics of a prototype drug with high hepatic extraction, and on hepatic microvascular blood flow (MVBF) after acute SCI. Pharmacokinetics of i.v. phenacetin was studied in rats 24 h after a severe T-5 spinal cord contusion; animals being pretreated with L-arginine 100 mg/kg i.v. or vehicle. MVBF was assessed under similar experimental conditions using laser Doppler flowmetry. SCI significantly altered phenacetin pharmacokinetics. Clearance was significantly reduced, resulting in a prolonged half-life and an increase in bioavailability, while volume of distribution was decreased. Pharmacokinetic alterations were reversed when injured rats were pretreated with L -arginine. It was also observed that L-arginine significantly increased hepatic MVBF in injured rats, notwithstanding it exhibited a limited effect on sham-injured animals. Our data hence suggest that L-arginine is able to reverse SCI-induced alterations in phenacetin pharmacokinetics due to an impaired hepatic MVBF, likely by increased nitric oxide synthesis leading to vasodilation. Further studies are warranted to examine the potential usefulness of nitric oxide supplementation in a clinical setting.
Vertiz-Hernandez
Antonio
A
School of Chemical Science, UJED, Durango, Mexico.
Castaneda-Hernandez
Gilberto
G
Martinez-Cruz
Angelina
A
Cruz-Antonio
Leticia
L
Grijalva
Israel
I
Guizar-Sahagun
Gabriel
G
D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics*; D000818:Animals; D001120:Arginine / Q000097:blood / Q000494:pharmacology*; D017078:Laser-Doppler Flowmetry; D008099:Liver / Q000098:blood supply* / Q000187:drug effects; D008102:Liver Circulation / Q000187:drug effects*; D008297:Male; D008657:Metabolic Clearance Rate; D010615:Phenacetin / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow / Q000187:drug effects; D013119:Spinal Cord Injuries / Q000503:physiopathology*
D018712:Analgesics, Non-Narcotic; D001120:Arginine; D010615:Phenacetin